Twist Bioscience Corporation

As of June 30, 2026, Twist Bioscience Corp. carries a market capitalization of 5.63B, placing it among publicly traded companies globally. Its enterprise value stands at 5.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Twist Bioscience Corp.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Twist Bioscience Corp. has 62.67M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 14.59, and the price-to-book ratio stands at 14.43.

These figures are as of June 30, 2026. The EV/Sales ratio of 14.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.57B versus a market cap of 5.63B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Twist Bioscience Corp. maintains a current ratio of 2.67, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Twist Bioscience Corp. posted a negative return on equity (ROE) of -29.59, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.78, reflecting losses generated across the asset base. The company generates approximately 386,060.05 in revenue per employee across its workforce of 979.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.79 indicates how many times Twist Bioscience Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Twist Bioscience Corp. recorded 756,259.20 in income tax expense. The company reported a pretax loss of -118.91M and -119.67M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Twist Bioscience Corp.'s stock has gained approximately 336.07% over the past 52 weeks. The 50-day moving average sits at 130.71, while the 200-day moving average is 74.73.

Over the twelve months ended June 30, 2026, Twist Bioscience Corp. generated 377.95M in revenue and converted that into -119.67M in net income, yielding earnings per share of -1.95. EBITDA reached -104.67M, while operating income came in at -120.77M.

As of June 30, 2026, Twist Bioscience Corp. holds 146.03M in cash and equivalents against 81.92M in total debt, resulting in a net debt position of -102.79M. Total book value stands at 390.16M, with working capital of 175.97M providing operational flexibility.

Twist Bioscience Corp. produced -46.45M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -35.06M in capital expenditures, free cash flow totaled -81.51M - equivalent to -1.33 per share.

Over the twelve months ended June 30, 2026, Twist Bioscience Corp. posted a gross margin of 51.97, reflecting its pricing power and cost economics. The operating margin of -31.95 and net profit margin of -31.66 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.48: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.21, meaning Twist Bioscience Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Twist Bioscience Corp. has an Altman Z-Score of 13.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.